**Table (4): Multinomial logistic regression analysis of factors associated with dengue complications (Dengue Hemorrhagic Fever and Dengue Shock Syndrome**)

|  |  |  |
| --- | --- | --- |
| Dengue Shock Syndrome  (n = 11) | Dengue Hemorrhagic Fever  (n = 280) | Variable |
| P- value  OR (95% CI) | |  |
| 0.000  608.2 (33.9-108.9) | 0.000  70.7 (38.4-129.9 | Presence of bleeding |
| 0.004  1.04 (1.015-1.08) | 0.001  1.9 (0.97-0.99) | Alanine aminotranferase level |
| 0.010  1.05 (1.012-1.088) | NS | Aspartate aminotransferase level |
| NS | 0.043  1.1 (0.191-0.974) | Urinary Proteins |
| NS | 0.027  1.4 (0.179-0.900) | Urinary Red blood cells |
| 0.014  0.16 (0.13-0.19) | NS | Platelet count on admsission less than 50,000 x 109/L |

N.B Results of significant predictors for either Dengue Hemorrhagic Fever or Dengue Shock Syndrome are included in the table

NS = Not significant

**Table (3): Comparison of Laboratory tests among patients with Dengue Fever, Dengue Hemorrhagic Fever and Dengue Shock Syndrome**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Test of significance | Total  (n = 977) | Dengue Shock Syndrome  (n = 11) | Dengue hemorrhagic  Fever  (n = 280) | Dengue fever  (n = 686) |  |
| X2 =94.3 ,  P = 0.000\* | 114 (11.7) | 8 (72.7) | 64 (22.9) | 42 (6.1) | Presense of Urinary Proteins, no. (%) |
| X2 =105.1,  P = 0.000\* | 121 (12.4) | 8 (72.7) | 71 (25.4) | 42 (6.1) | Presence of Urinary Red blood cells, no. (%) |
| K= 20.5,  P = 0.000\* | 66000  (5800-1410000) | 35000  (15000-114000) | 61000  (5800-429000) | 70500  (5800-1410000) | Platelets (x 109/L) at admission, Median (range) |
| K=36.6,  P = 0.000\* | 60000  (1800-185000) | 26000  (9000-34000) | 50000  (5000-185000) | 65000  (1800-185000) | Platelets (x 109/L) during admission, Median (range) |
| K=45.7,  P = 0.000\* | 51000  (7000-1110000) | 18000  (10000-28000) | 45000  (7000-890000) | 56000  (7000-1110000) | Platelets (x 109/L) on discharge, Median ( range) |
| K=19.3,  P = 0.000\* | 58 (9-189) | 133 (9-140) | 56 (23-186) | 58 (11-189) | Asparate aminotranferase (IU/ml), Median (range) |
| K=32.7,  P = 0.000\* | 56 (14-186) | 125 (98-182) | 56 (29-186) | 56 (14-184) | Alanine aminotranferase (IU/ml), Median (range) |

X2 (chi-square test)- K (Kruskal Wallis Test)

\* Significant (P < 0.05)

**Table (2): Comparison of symptoms among patients with Dengue Fever (DF), Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Test of significance | Total  (n = 977) | DSS  (n = 11) | DHF  (n = 280) | DF  (n = 686) | Presence of symptom |
| MCE,  P =0.095 | 969 (99.2) | 11 (100) | 274 (97.9) | 684 (99.7) | Headache, no. (%) |
| MCE,  P =0.592 | 975 (99.8) | 11 (100) | 280 (100) | 684 (99.7) | High fever, no. (%) |
| X2 =7.1 ,  P = 0.029\* | 247(25.3) | 3(27.3) | 87(31.1) | 157 (22.9) | Backache, no. (%) |
| X2 =168 ,  P = 0.000\* | 19 (1.9) | 6(54.5) | 9(3.2) | 4(0.6) | Encephalitis, no. (%) |
| X2 =88.6 ,  P = 0.000\* | 299 (30.6) | 10(90.9) | 275(98.6) | 14(2.0) | Bleeding, no. (%) |
| X2 =.68 ,  P = 0.710 | 598 (61.3) | 8 (72.7) | 173 (61.8) | 417 (60.9) | Vomiting, no. (%) |
| X2 =7.3 ,  P = 0.027\* | 420 (43.2) | 1 (9.1) | 131 (47.1) | 288 (42.2) | Rash, no. (%) |
| X2 =.59 ,  P = 0.743 | 522 (53.5) | 7 (63.6) | 152 (54.3) | 363 (53.0) | Abdominal pain, no. (%) |
| X2 =1.3 ,  P = 0.522 | 273 (27.9) | 4 (36.4) | 84 (30.0) | 185 (27.0) | Ascites, no. (%) |
| X2 =1.8 ,  P = 0.402 | 216 (22.3) | 4 (36.4) | 66 (23.7) | 146 (21.5) | Pleural effusion, no. (%) |

X2 (chi-square test)- MCE (Monte Carlo exact test)

\* Significant (P < 0.05)

**Table (1): Characteristics of dengue patients according to final diagnosis**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Test of significance | Total  (n = 977) | Dengue shock syndrome  (n = 11) | Dengue hemorrhagic Fever  (n = 280) | Dengue fever  (n = 686) | Variables |
| F =1.2 ,  P = 0.303 | 39.9 ±16.7 | 47.5 ±18.9 | 39.9 ± 17.3 | 39.7 ±16.7 | Age  (mean± SD) |
| X2 =7.8 ,  P = 0.020\* | 691(70.7) | 4(0.6) | 207(30) | 480 (69.5) | Male, no. (%) |
|  |  |  |  |  | Outcome, no. (%) |
| MCE,  P = 0.053 | 948 (97.3) | 11(100) | 276(98.9) | 660(96.6) | * Recovery |
| 27 (2.6) | 0 | 2(0.7) | 23(3.4) | * LAMA |
| 1 (0.1) | 0 | 1(0.4) | 0 | * Death |
| X2 =105.1 ,  P = 0.000\* | 121 (12.4) | 8 (72.7) | 71 (25.4) | 42 (6.1) | Intervention, no. (%) |
| X2 =2.4 ,  P = 0.300 | 518 (83.4) | 10(90.9) | 226(80.7) | 579(84.4) | Positive IgM,  No. (%) |
| X2 =13.8 ,  P = 0.001\* | 617 (63.2) | 9(81.8) | 200(71.4) | 408(59.5) | Positive IgG,  No. (%) |

F (ANOVA test)- X2 (chi-square test)- MCE (Monte Carlo exact test)

SD= Standard Deviation

LAMA= Left Against Medical Advice

\* Significant (P < 0.05)